Cargando…
Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study
PURPOSE: To evaluate vasomotor symptoms and soy and hormone therapy use in women who had previously participated in the Soy Estrogen Alternative (SEA) study, a trial conducted to compare the effects of soy protein supplements containing differing levels of isoflavones on menopausal symptoms, chronic...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990907/ https://www.ncbi.nlm.nih.gov/pubmed/21151685 http://dx.doi.org/10.2147/IJWH.S12863 |
_version_ | 1782192534954442752 |
---|---|
author | Vitolins, Mara Z Case, L Douglas Morgan, Timothy M Miller, Margaret A Burke, Gregory L |
author_facet | Vitolins, Mara Z Case, L Douglas Morgan, Timothy M Miller, Margaret A Burke, Gregory L |
author_sort | Vitolins, Mara Z |
collection | PubMed |
description | PURPOSE: To evaluate vasomotor symptoms and soy and hormone therapy use in women who had previously participated in the Soy Estrogen Alternative (SEA) study, a trial conducted to compare the effects of soy protein supplements containing differing levels of isoflavones on menopausal symptoms, chronic disease risk factors, and health-related quality of life in perimenopausal and postmenopausal women. PARTICIPANTS AND METHODS: Two years after the SEA study ended participants were recontacted to complete questionnaires to quantify their health status, medications, menopausal symptoms, and their use of hormone therapy and soy-based foods and supplements. Participants were also asked to record vasomotor symptoms for seven days. RESULTS: Surveys were collected from 182 of the 241 participants who had been enrolled in the SEA study (76% response rate). Women were 55 ± 2.8 years of age, well educated (80% more than high school), and 93% reported good to excellent health. All but six reported experiencing at least one menopausal symptom, and 56% reported one or more hot flashes on one or more days. Eighty-one women (45%) continued to use soy for menopausal symptom relief, and 58 (32%) were using hormone therapy. Women taking hormone therapy were experiencing fewer and less severe hot flashes than those who were not taking hormone therapy (P < 0.001); hot flash frequency and severity did not differ significantly between those who did and did not use soy, after controlling for hormone therapy use. CONCLUSION: Most participants reported they were still experiencing menopausal symptoms. Additionally, half of the most symptomatic women (not taking hormone therapy) were still consuming soy products for vasomotor symptoms. |
format | Text |
id | pubmed-2990907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-29909072010-12-13 Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study Vitolins, Mara Z Case, L Douglas Morgan, Timothy M Miller, Margaret A Burke, Gregory L Int J Womens Health Original Research PURPOSE: To evaluate vasomotor symptoms and soy and hormone therapy use in women who had previously participated in the Soy Estrogen Alternative (SEA) study, a trial conducted to compare the effects of soy protein supplements containing differing levels of isoflavones on menopausal symptoms, chronic disease risk factors, and health-related quality of life in perimenopausal and postmenopausal women. PARTICIPANTS AND METHODS: Two years after the SEA study ended participants were recontacted to complete questionnaires to quantify their health status, medications, menopausal symptoms, and their use of hormone therapy and soy-based foods and supplements. Participants were also asked to record vasomotor symptoms for seven days. RESULTS: Surveys were collected from 182 of the 241 participants who had been enrolled in the SEA study (76% response rate). Women were 55 ± 2.8 years of age, well educated (80% more than high school), and 93% reported good to excellent health. All but six reported experiencing at least one menopausal symptom, and 56% reported one or more hot flashes on one or more days. Eighty-one women (45%) continued to use soy for menopausal symptom relief, and 58 (32%) were using hormone therapy. Women taking hormone therapy were experiencing fewer and less severe hot flashes than those who were not taking hormone therapy (P < 0.001); hot flash frequency and severity did not differ significantly between those who did and did not use soy, after controlling for hormone therapy use. CONCLUSION: Most participants reported they were still experiencing menopausal symptoms. Additionally, half of the most symptomatic women (not taking hormone therapy) were still consuming soy products for vasomotor symptoms. Dove Medical Press 2010-11-02 /pmc/articles/PMC2990907/ /pubmed/21151685 http://dx.doi.org/10.2147/IJWH.S12863 Text en © 2010 Vitolins et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Vitolins, Mara Z Case, L Douglas Morgan, Timothy M Miller, Margaret A Burke, Gregory L Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study |
title | Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study |
title_full | Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study |
title_fullStr | Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study |
title_full_unstemmed | Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study |
title_short | Soy use and vasomotor symptoms: Soy Estrogen Alternative follow-up study |
title_sort | soy use and vasomotor symptoms: soy estrogen alternative follow-up study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990907/ https://www.ncbi.nlm.nih.gov/pubmed/21151685 http://dx.doi.org/10.2147/IJWH.S12863 |
work_keys_str_mv | AT vitolinsmaraz soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy AT caseldouglas soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy AT morgantimothym soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy AT millermargareta soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy AT burkegregoryl soyuseandvasomotorsymptomssoyestrogenalternativefollowupstudy |